CRC
CLSD

Curi RMB Capital’s Clearside Biomedical CLSD Stock Holding History

Curi RMB Capital’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,667
Closed -$32.5K – 545
2024
Q2 		$32.5K Hold
1,667
– – ﹤0.01% 526
2024
Q1 		$38.3K Buy
+1,667
New +$35.9K ﹤0.01% 560

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Curi RMB Capital's CLSD Position: Q3 2024 in Review

Curi RMB Capital sold out of Clearside Biomedical (CLSD) in Q3 2024, closing a stake of 1,667 shares — an estimated $32.5K sold.

Curi RMB Capital first reported a position in CLSD in Q1 2024 and held it in 2 quarters. The position peaked at $38.3K in Q1 2024. 48 funds tracked by Wall St. Rank hold CLSD as of Q3 2024.

  • Curi RMB Capital reported no remaining Clearside Biomedical position as of Q3 2024 after selling out during the quarter.
  • Curi RMB Capital sold 1,667 Clearside Biomedical shares in Q3 2024, an estimated $32.5K.
  • Curi RMB Capital first reported a position in Clearside Biomedical in Q1 2024 and held it in 2 quarters.
  • Curi RMB Capital's Clearside Biomedical position peaked at $38.3K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2024.

Based on Curi RMB Capital's 13F filing for Q3 2024, filed 6 Nov 2024.